Tislelizumab NSCLC Inclusion Recommended for Du...

By HEOR Staff Writer

February 9, 2026

Tislelizumab NSCLC Inclusion in Dutch Basic Package Zorginstituut Nederland's Tislelizumab NSCLC Inclusion Recommendation Zorginstituut Nederland's advis...
AI Healthcare Costs: Navigating Financial Hurdles in Technology Integration
NICE Endorses Dupilumab for Eosinophilic COPD Treatment
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Trump Economic Revival: Key Policies and Impacts from Davos 2026
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
Guiding Principles for Ethical AI Integration in Drug Development
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry...
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...